PARP1 and Hepatic fibrosis: Regarding the treatment of chronic inflammation and liver diseases, pharmacological inhibition of PARP or genetic deletion of PARP1 was able to reduce chronic inflammation and fibrosis induced by the treatment with CCl4 in mice [146], and also attenuated the development of hepatic fibrosis, bile duct ligation-induced, in mice [146].